['acute myeloid leukemia', 'hematopoietic stem cell transplantation']
['sorafenib']

        Inclusion Criteria:

          -  FLT3-ITD Positive AML

          -  Allo-HSCT Recipients

        Exclusion Criteria:

          -  cardiac dysfunction (particularly congestive heart failure)

          -  hepatic abnormalities (bilirubin ≥ 3 mg/dL, aminotransferase> 2 times the upper limit
             of normal)

          -  renal dysfunction (creatinine clearance rate < 30 mL/min)

          -  Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood
             pressure)

          -  Patients with any conditions not suitable for the trial (investigators' decision)
      